Discovery of plasmodium inhibitors as clinical candidates to treat Malaria

This post-doc will work in collaboration with expert scientists from the Medicines for Malaria Venture (MMV, www.mmv.org) and have access to a very well organized framework providing an integrated approach to modern drug discovery. The overall goal with MMV is to deliver a clinical candidate to treat Malaria, as defined by the criteria for an MMV Preclinical candidate. Such a compound should have the potential to be developed, in combination, to deliver a single exposure radical cure and prophylaxis or single exposure chemoprotection drug. A clinical candidate broadly speaking needs to have potency against relevant parasites, a low propensity to generate resistance, have oral efficacy in rodent models, good developability, a good safety profile and low cost of goods. MMV will provide the project with quality lead molecules, aligned to a particular Target Product Profile (TPP) of interest. The post-doc will investigate structure-activity relationships in these series in order to further optimize them and deliver drug candidates, as well as to aim to elucidate novel mechanisms of action.

Project details

Product Development

Apr 2021 — Mar 2023

Brazil